Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients


Por: Estival A, Sanz C, Ramirez J, Velarde J, Domenech M, Carrato C, de las Penas R, Gil-Gil M, Sepulveda J, Armengol R, Cardiel I, Berrocal A, Luque R, Herrero A, Balana C

Publicada: 31 jul 2019
Resumen:
Circulating biomarkers in blood may provide an interesting alternative to risky tissue biopsies in the diagnosis and follow-up of glioblastoma patients. We have assessed MGMT methylation status in blood and tissue samples from unresected glioblastoma patients who had been included in the randomized GENOM-009 trial. Paired blood and tissue samples were assessed by methylation-specific PCR (MSP) and pyrosequencing (PYR). After establishing the minimum PYR cut-off that could yield a significant difference in overall survival, we assessed the sensitivity, specificity, positive predictive value and negative predictive value (NPV) of the analyses. Methylation could be detected in cfDNA by both MSP and PYR but with low concordance with results in tissue. Sensitivity was low for both methods (31% and 38%, respectively), while specificity was higher for MSP in blood than for PYR in plasma (96% vs 76%) and NPV was similar (56 vs 57%). Concordance of results in tissue by MSP and PYR was 84.3% (P < 0.001) and correlated with outcome. We conclude that detection of cfDNA in the blood of glioblastoma patients can be an alternative when tumor tissue is not available but methods for the detection of cfDNA in blood must improve before it can replace analysis in tumor tissue.

Filiaciones:
Estival A:
 Hosp Badalona Germans Trias & Pujol, Appl Res Grp Oncol B ARGO Grp, Med Oncol Serv, Catalan Inst Oncol Badalona, Badalona, Spain

Sanz C:
 Hosp Badalona Germans Trias & Pujol, Pathol Serv, Badalona, Spain

Ramirez J:
 Hosp Badalona Germans Trias & Pujol, Appl Res Grp Oncol B ARGO Grp, Med Oncol Serv, Catalan Inst Oncol Badalona, Badalona, Spain

Velarde J:
 Inst Invest Germans Trias & Pujol IGTP, Appl Res Grp Oncol B ARGO Grp, Stat Unit, Badalona, Spain

Domenech M:
 Hosp Badalona Germans Trias & Pujol, Appl Res Grp Oncol B ARGO Grp, Med Oncol Serv, Catalan Inst Oncol Badalona, Badalona, Spain

Carrato C:
 Hosp Badalona Germans Trias & Pujol, Pathol Serv, Badalona, Spain

de las Penas R:
 Hosp Prov Castellon, Med Oncol Serv, Castellon de La Plana, Spain

Gil-Gil M:
 Catalan Inst Oncol lHospitalet de LLobregat, Med Oncol Serv, Bellvitge Biomed Res Inst IDIBELL lHospitalet Llo, Barcelona, Spain

Sepulveda J:
 Univ Hosp 12 Octubre, Med Oncol Serv, Madrid, Spain

Armengol R:
 Hosp Badalona Germans Trias & Pujol, Neurosurg Serv, Badalona, Spain

Cardiel I:
 Hosp Badalona Germans Trias & Pujol, Neurosurg Serv, Badalona, Spain

Berrocal A:
 Univ Hosp Gen Valencia, Med Oncol Serv, Valencia, Spain

Luque R:
 Univ Hosp Virgen de las Nieves, Med Oncol Serv, Granada, Spain

Herrero A:
 Hosp Miguel Servet, Med Oncol Serv, Zaragoza, Spain

Balana C:
 Hosp Badalona Germans Trias & Pujol, Appl Res Grp Oncol B ARGO Grp, Med Oncol Serv, Catalan Inst Oncol Badalona, Badalona, Spain
ISSN: 20452322





Scientific Reports
Editorial
NATURE PUBLISHING GROUP, MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 9 Número:
Páginas:
WOS Id: 000477950800048
ID de PubMed: 31366977

MÉTRICAS